Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials [1][5] - The company presented research on the immunomodulatory potential of human dermal fibroblast spheroids in psoriasis therapy at the Society for Investigative Dermatology Annual Meeting [2][3] Company Overview - FibroBiologics holds over 240 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [5] - The company aims to advance innovative, cell-based treatments for chronic inflammatory diseases, with a focus on providing durable therapeutic options with lower adverse side effects [3][5] Research Highlights - The poster presentation titled "Immunomodulatory Potential of Human Dermal Fibroblast Spheroids in Psoriasis Therapy" demonstrated the potential of HDF spheroids to reduce psoriasis severity in preclinical models [2] - The research indicates that fibroblast-based candidates may offer sustained remission and reduced relapse rates in psoriasis treatment [3]